Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 227

1.

Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicine for acute myeloid leukemia in elderly patients.

Röllig C, Kramer M, Gabrecht M, Hänel M, Herbst R, Kaiser U, Schmitz N, Kullmer J, Fetscher S, Link H, Mantovani-Löffler L, Krümpelmann U, Neuhaus T, Heits F, Einsele H, Ritter B, Bornhäuser M, Schetelig J, Thiede C, Mohr B, Schaich M, Platzbecker U, Schäfer-Eckart K, Krämer A, Berdel WE, Serve H, Ehninger G, Schuler U; Study Alliance Leukemia (SAL).

Ann Oncol. 2018 Jan 30. doi: 10.1093/annonc/mdy030. [Epub ahead of print]

PMID:
29390048
2.

Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantation.

Pfeifer H, Raum K, Markovic S, Nowak V, Fey S, Obländer J, Pressler J, Böhm V, Brüggemann M, Wunderle L, Hüttmann A, Wäsch R, Beck J, Stelljes M, Viardot A, Lang F, Hoelzer D, Hofmann WK, Serve H, Weiss C, Goekbuget N, Ottmann OG, Nowak D.

Blood. 2018 Mar 29;131(13):1464-1475. doi: 10.1182/blood-2017-07-796862. Epub 2018 Jan 18.

PMID:
29348129
3.

Clinical impact of colonization with multidrug-resistant organisms on outcome after allogeneic stem cell transplantation in patients with acute myeloid leukemia.

Scheich S, Lindner S, Koenig R, Reinheimer C, Wichelhaus TA, Hogardt M, Besier S, Kempf VAJ, Kessel J, Martin H, Wilke AC, Serve H, Bug G, Steffen B.

Cancer. 2018 Jan 15;124(2):286-296. doi: 10.1002/cncr.31045. Epub 2017 Sep 28.

PMID:
28960264
4.

Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations.

Heidrich K, Thiede C, Schäfer-Eckart K, Schmitz N, Aulitzky WE, Krämer A, Rösler W, Hänel M, Einsele H, Baldus CD, Trappe RU, Stölzel F, Middeke JM, Röllig C, Taube F, Kramer M, Serve H, Berdel WE, Ehninger G, Bornhäuser M, Schetelig J; Study Alliance Leukemia (SAL).

Ann Oncol. 2017 Nov 1;28(11):2793-2798. doi: 10.1093/annonc/mdx500.

PMID:
28945881
5.

SOCS1 function in BCR-ABL mediated myeloproliferative disease is dependent on the cytokine environment.

Demirel Ö, Balló O, Reddy PNG, Vakhrusheva O, Zhang J, Eichler A, Fernandes R, Badura S, Serve H, Brandts C.

PLoS One. 2017 Jul 28;12(7):e0180401. doi: 10.1371/journal.pone.0180401. eCollection 2017.

6.

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial).

Bug G, Burchert A, Wagner EM, Kröger N, Berg T, Güller S, Metzelder SK, Wolf A, Hünecke S, Bader P, Schetelig J, Serve H, Ottmann OG.

Leukemia. 2017 Nov;31(11):2523-2525. doi: 10.1038/leu.2017.242. Epub 2017 Jul 28. No abstract available.

7.

AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia.

Zhou F, Liu Y, Rohde C, Pauli C, Gerloff D, Köhn M, Misiak D, Bäumer N, Cui C, Göllner S, Oellerich T, Serve H, Garcia-Cuellar MP, Slany R, Maciejewski JP, Przychodzen B, Seliger B, Klein HU, Bartenhagen C, Berdel WE, Dugas M, Taketo MM, Farouq D, Schwartz S, Regev A, Hébert J, Sauvageau G, Pabst C, Hüttelmaier S, Müller-Tidow C.

Nat Cell Biol. 2017 Jul;19(7):844-855. doi: 10.1038/ncb3563. Epub 2017 Jun 26.

PMID:
28650479
8.

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.

Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Döhner H.

N Engl J Med. 2017 Aug 3;377(5):454-464. doi: 10.1056/NEJMoa1614359. Epub 2017 Jun 23.

9.

Corrigendum: SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.

Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, Flick R, Bohnenberger H, Kaderali L, Stegmann L, Cremer A, Martin M, Lohmeyer J, Michaelis M, Hornung V, Schliemann C, Berdel WE, Hartmann W, Wardelmann E, Comoglio F, Hansmann ML, Yakunin AF, Geisslinger G, Ströbel P, Ferreirós N, Serve H, Keppler OT, Cinatl J Jr.

Nat Med. 2017 Jun 6;23(6):788. doi: 10.1038/nm0617-788a. No abstract available.

PMID:
28586337
10.

Clinical Impact of Colonization with Multidrug-Resistant Organisms on Outcome after Autologous Stem Cell Transplantation: A Retrospective Single-Center Study.

Scheich S, Reinheimer C, Brandt C, Wichelhaus TA, Hogardt M, Kempf VAJ, Brunnberg U, Brandts C, Ballo O, von Metzler I, Kessel J, Serve H, Steffen B.

Biol Blood Marrow Transplant. 2017 Sep;23(9):1455-1462. doi: 10.1016/j.bbmt.2017.05.016. Epub 2017 May 18.

PMID:
28528711
11.

Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia.

Mohr S, Doebele C, Comoglio F, Berg T, Beck J, Bohnenberger H, Alexe G, Corso J, Ströbel P, Wachter A, Beissbarth T, Schnütgen F, Cremer A, Haetscher N, Göllner S, Rouhi A, Palmqvist L, Rieger MA, Schroeder T, Bönig H, Müller-Tidow C, Kuchenbauer F, Schütz E, Green AR, Urlaub H, Stegmaier K, Humphries RK, Serve H, Oellerich T.

Cancer Cell. 2017 Apr 10;31(4):549-562.e11. doi: 10.1016/j.ccell.2017.03.001.

12.

Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape.

Silva P, Neumann M, Schroeder MP, Vosberg S, Schlee C, Isaakidis K, Ortiz-Tanchez J, Fransecky LR, Hartung T, Türkmen S, Graf A, Krebs S, Blum H, Müller-Tidow C, Thiede C, Ehninger G, Serve H, Hecht J, Berdel WE, Greif PA, Röllig C, Baldus CD.

Leukemia. 2017 Jul;31(7):1640-1644. doi: 10.1038/leu.2017.109. Epub 2017 Apr 3. No abstract available.

PMID:
28366934
13.

Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient.

Herold S, Kuhn M, Bonin MV, Stange T, Platzbecker U, Radke J, Lange T, Sockel K, Gutsche K, Schetelig J, Röllig C, Schuster C, Roeder I, Dahl A, Mohr B, Serve H, Brandts C, Ehninger G, Bornhäuser M, Thiede C.

Leukemia. 2017 Jul;31(7):1637-1640. doi: 10.1038/leu.2017.104. Epub 2017 Mar 28. No abstract available.

PMID:
28348390
14.

RUNX1 cooperates with FLT3-ITD to induce leukemia.

Behrens K, Maul K, Tekin N, Kriebitzsch N, Indenbirken D, Prassolov V, Müller U, Serve H, Cammenga J, Stocking C.

J Exp Med. 2017 Mar 6;214(3):737-752. doi: 10.1084/jem.20160927. Epub 2017 Feb 17.

15.

HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling.

Walter R, Pan KT, Doebele C, Comoglio F, Tomska K, Bohnenberger H, Young RM, Jacobs L, Keller U, Bönig H, Engelke M, Rosenwald A, Urlaub H, Staudt LM, Serve H, Zenz T, Oellerich T.

Blood. 2017 Feb 2;129(5):598-608. doi: 10.1182/blood-2016-06-721423. Epub 2016 Nov 15.

16.

SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.

Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, Flick R, Bohnenberger H, Kaderali L, Stegmann L, Cremer A, Martin M, Lohmeyer J, Michaelis M, Hornung V, Schliemann C, Berdel WE, Hartmann W, Wardelmann E, Comoglio F, Hansmann ML, Yakunin AF, Geisslinger G, Ströbel P, Ferreirós N, Serve H, Keppler OT, Cinatl J Jr.

Nat Med. 2017 Feb;23(2):250-255. doi: 10.1038/nm.4255. Epub 2016 Dec 19. Erratum in: Nat Med. 2017 Jun 6;23 (6):788.

PMID:
27991919
17.

Plastic CD34 and CD38 expression in adult B-cell precursor acute lymphoblastic leukemia explains ambiguity of leukemia-initiating stem cell populations.

Lang F, Wojcik B, Bothur S, Knecht C, Falkenburg JH, Schroeder T, Serve H, Ottmann OG, Rieger MA.

Leukemia. 2017 Mar;31(3):731-734. doi: 10.1038/leu.2016.315. Epub 2016 Nov 2. No abstract available.

18.

Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia.

Göllner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein HU, Rohde C, Pabst C, Sauer T, Lerdrup M, Tavor S, Stölzel F, Herold S, Ehninger G, Köhler G, Pan KT, Urlaub H, Serve H, Dugas M, Spiekermann K, Vick B, Jeremias I, Berdel WE, Hansen K, Zelent A, Wickenhauser C, Müller LP, Thiede C, Müller-Tidow C.

Nat Med. 2017 Jan;23(1):69-78. doi: 10.1038/nm.4247. Epub 2016 Dec 12.

PMID:
27941792
19.

Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis.

Thol F, Klesse S, Köhler L, Gabdoulline R, Kloos A, Liebich A, Wichmann M, Chaturvedi A, Fabisch J, Gaidzik VI, Paschka P, Bullinger L, Bug G, Serve H, Göhring G, Schlegelberger B, Lübbert M, Kirchner H, Wattad M, Kraemer D, Hertenstein B, Heil G, Fiedler W, Krauter J, Schlenk RF, Döhner K, Döhner H, Ganser A, Heuser M.

Leukemia. 2017 Jun;31(6):1286-1295. doi: 10.1038/leu.2016.345. Epub 2016 Nov 24.

PMID:
27881874
20.

Health care setting and severity, symptom burden, and complications in patients with Philadelphia-negative myeloproliferative neoplasms (MPN): a comparison between university hospitals, community hospitals, and office-based physicians.

Kaifie A, Isfort S, Gattermann N, Hollburg W, Klausmann M, Wolf D, Maintz C, Hänel M, Goekkurt E, Göthert JR, Platzbecker U, Geer T, Parmentier S, Jost E, Serve H, Ehninger G, Berdel WE, Brümmendorf TH, Koschmieder S; Study Alliance Leukemia (SAL).

Ann Hematol. 2016 Sep;95(9):1399-410. doi: 10.1007/s00277-016-2730-y. Epub 2016 Jun 22.

PMID:
27334946
21.

Elucidation of tonic and activated B-cell receptor signaling in Burkitt's lymphoma provides insights into regulation of cell survival.

Corso J, Pan KT, Walter R, Doebele C, Mohr S, Bohnenberger H, Ströbel P, Lenz C, Slabicki M, Hüllein J, Comoglio F, Rieger MA, Zenz T, Wienands J, Engelke M, Serve H, Urlaub H, Oellerich T.

Proc Natl Acad Sci U S A. 2016 May 17;113(20):5688-93. doi: 10.1073/pnas.1601053113. Epub 2016 May 6.

22.

Selective AKT Inhibition by MK-2206 Represses Colorectal Cancer-Initiating Stem Cells.

Malkomes P, Lunger I, Luetticke A, Oppermann E, Haetscher N, Serve H, Holzer K, Bechstein WO, Rieger MA.

Ann Surg Oncol. 2016 Sep;23(9):2849-57. doi: 10.1245/s10434-016-5218-z. Epub 2016 Apr 8.

23.

Mismatched unrelated hematopoietic stem cell transplantation with post-transplant cyclophosphamide for high-risk acute myeloid leukemia.

Lindner S, Berg T, Riemann J, Ajib S, Jedlickova Z, Gueller S, Lang F, Martin H, Serve H, Bacigalupo A, Bug G.

Ann Hematol. 2016 May;95(6):1023-5. doi: 10.1007/s00277-016-2652-8. Epub 2016 Apr 8. No abstract available.

PMID:
27056199
24.

Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia.

Büchner T, Krug UO, Peter Gale R, Heinecke A, Sauerland MC, Haferlach C, Schnittger S, Haferlach T, Müller-Tidow C, Stelljes M, Mesters RM, Serve HL, Braess J, Spiekermann K, Staib P, Grüneisen A, Reichle A, Balleisen L, Eimermacher H, Giagounidis A, Rasche H, Lengfelder E, Görlich D, Faldum A, Köpcke W, Hehlmann R, Wörmann BJ, Berdel WE, Hiddemann W.

Leukemia. 2016 Aug;30(8):1781-4. doi: 10.1038/leu.2016.54. Epub 2016 Mar 11. No abstract available.

PMID:
26965440
25.

Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.

Kaifie A, Kirschner M, Wolf D, Maintz C, Hänel M, Gattermann N, Gökkurt E, Platzbecker U, Hollburg W, Göthert JR, Parmentier S, Lang F, Hansen R, Isfort S, Schmitt K, Jost E, Serve H, Ehninger G, Berdel WE, Brümmendorf TH, Koschmieder S; Study Alliance Leukemia (SAL).

J Hematol Oncol. 2016 Mar 5;9:18. doi: 10.1186/s13045-016-0242-9.

26.

Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia.

Krug U, Berdel WE, Gale RP, Haferlach C, Schnittger S, Müller-Tidow C, Braess J, Spiekermann K, Staib P, Beelen D, Serve H, Schliemann C, Stelljes M, Balleisen L, Maschmeyer G, Grüneisen A, Eimermacher H, Giagounidis A, Rasche H, Hehlmann R, Lengfelder E, Thiel E, Reichle A, Aul C, Ludwig WD, Kern W, Haferlach T, Köpcke W, Görlich D, Sauerland MC, Heinecke A, Wörmann BJ, Hiddemann W, Büchner T.

Leukemia. 2016 Jun;30(6):1230-6. doi: 10.1038/leu.2016.25. Epub 2016 Feb 9.

PMID:
26859081
27.

Karyotype complexity and prognosis in acute myeloid leukemia.

Stölzel F, Mohr B, Kramer M, Oelschlägel U, Bochtler T, Berdel WE, Kaufmann M, Baldus CD, Schäfer-Eckart K, Stuhlmann R, Einsele H, Krause SW, Serve H, Hänel M, Herbst R, Neubauer A, Sohlbach K, Mayer J, Middeke JM, Platzbecker U, Schaich M, Krämer A, Röllig C, Schetelig J, Bornhäuser M, Ehninger G.

Blood Cancer J. 2016 Jan 15;6:e386. doi: 10.1038/bcj.2015.114.

28.

TP53 mutation in patients with high-risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation.

Middeke JM, Herold S, Rücker-Braun E, Berdel WE, Stelljes M, Kaufmann M, Schäfer-Eckart K, Baldus CD, Stuhlmann R, Ho AD, Einsele H, Rösler W, Serve H, Hänel M, Sohlbach K, Klesse C, Mohr B, Heidenreich F, Stölzel F, Röllig C, Platzbecker U, Ehninger G, Bornhäuser M, Thiede C, Schetelig J; Study Alliance Leukaemia (SAL).

Br J Haematol. 2016 Mar;172(6):914-22. doi: 10.1111/bjh.13912. Epub 2016 Jan 13.

PMID:
26771088
29.

STAT5-regulated microRNA-193b controls haematopoietic stem and progenitor cell expansion by modulating cytokine receptor signalling.

Haetscher N, Feuermann Y, Wingert S, Rehage M, Thalheimer FB, Weiser C, Bohnenberger H, Jung K, Schroeder T, Serve H, Oellerich T, Hennighausen L, Rieger MA.

Nat Commun. 2015 Nov 25;6:8928. doi: 10.1038/ncomms9928.

30.

ATR inhibition rewires cellular signaling networks induced by replication stress.

Wagner SA, Oehler H, Voigt A, Dalic D, Freiwald A, Serve H, Beli P.

Proteomics. 2016 Feb;16(3):402-16. doi: 10.1002/pmic.201500172.

PMID:
26572502
31.

Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.

Ho AD, Schetelig J, Bochtler T, Schaich M, Schäfer-Eckart K, Hänel M, Rösler W, Einsele H, Kaufmann M, Serve H, Berdel WE, Stelljes M, Mayer J, Reichle A, Baldus CD, Schmitz N, Kramer M, Röllig C, Bornhäuser M, Thiede C, Ehninger G; Study Alliance Leukemia.

Biol Blood Marrow Transplant. 2016 Mar;22(3):462-9. doi: 10.1016/j.bbmt.2015.10.023. Epub 2015 Nov 10.

32.

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.

Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD, Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE, Ehninger G; Study Alliance Leukaemia.

Lancet Oncol. 2015 Dec;16(16):1691-9. doi: 10.1016/S1470-2045(15)00362-9. Epub 2015 Nov 6.

PMID:
26549589
33.

Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.

Müller-Tidow C, Tschanter P, Röllig C, Thiede C, Koschmieder A, Stelljes M, Koschmieder S, Dugas M, Gerss J, Butterfaß-Bahloul T, Wagner R, Eveslage M, Thiem U, Krause SW, Kaiser U, Kunzmann V, Steffen B, Noppeney R, Herr W, Baldus CD, Schmitz N, Götze K, Reichle A, Kaufmann M, Neubauer A, Schäfer-Eckart K, Hänel M, Peceny R, Frickhofen N, Kiehl M, Giagounidis A, Görner M, Repp R, Link H, Kiani A, Naumann R, Brümmendorf TH, Serve H, Ehninger G, Berdel WE, Krug U; Study Alliance Leukemia Group.

Leukemia. 2016 Mar;30(3):555-61. doi: 10.1038/leu.2015.306. Epub 2015 Nov 2.

PMID:
26522083
34.

The Phosphatases STS1 and STS2 Regulate Hematopoietic Stem and Progenitor Cell Fitness.

Zhang J, Vakhrusheva O, Bandi SR, Demirel Ö, Kazi JU, Fernandes RG, Jakobi K, Eichler A, Rönnstrand L, Rieger MA, Carpino N, Serve H, Brandts CH.

Stem Cell Reports. 2015 Oct 13;5(4):633-46. doi: 10.1016/j.stemcr.2015.08.006. Epub 2015 Sep 10.

35.

NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells.

Jayavelu AK, Müller JP, Bauer R, Böhmer SA, Lässig J, Cerny-Reiterer S, Sperr WR, Valent P, Maurer B, Moriggl R, Schröder K, Shah AM, Fischer M, Scholl S, Barth J, Oellerich T, Berg T, Serve H, Frey S, Fischer T, Heidel FH, Böhmer FD.

Leukemia. 2016 Feb;30(2):473-83. doi: 10.1038/leu.2015.234. Epub 2015 Aug 26.

PMID:
26308771
36.

A high BMI is a risk factor in younger patients with de novo acute myelogenous leukemia.

Crysandt M, Kramer M, Ehninger G, Bornhäuser M, Berdel WE, Serve H, Röllig C, Kaifie A, Jost E, Brummendorf TH, Wilop S.

Eur J Haematol. 2016 Jul;97(1):17-24. doi: 10.1111/ejh.12675. Epub 2015 Sep 17.

PMID:
26277604
37.

RUNX1 represses the erythroid gene expression program during megakaryocytic differentiation.

Kuvardina ON, Herglotz J, Kolodziej S, Kohrs N, Herkt S, Wojcik B, Oellerich T, Corso J, Behrens K, Kumar A, Hussong H, Urlaub H, Koch J, Serve H, Bonig H, Stocking C, Rieger MA, Lausen J.

Blood. 2015 Jun 4;125(23):3570-9. doi: 10.1182/blood-2014-11-610519. Epub 2015 Apr 24.

38.

Quantitative mass spectrometric profiling of cancer-cell proteomes derived from liquid and solid tumors.

Bohnenberger H, Ströbel P, Mohr S, Corso J, Berg T, Urlaub H, Lenz C, Serve H, Oellerich T.

J Vis Exp. 2015 Feb 27;(96):e52435. doi: 10.3791/52435.

39.

FLT3-ITD and TLR9 use Bruton tyrosine kinase to activate distinct transcriptional programs mediating AML cell survival and proliferation.

Oellerich T, Mohr S, Corso J, Beck J, Döbele C, Braun H, Cremer A, Münch S, Wicht J, Oellerich MF, Bug G, Bohnenberger H, Perske C, Schütz E, Urlaub H, Serve H.

Blood. 2015 Mar 19;125(12):1936-47. doi: 10.1182/blood-2014-06-585216. Epub 2015 Jan 20.

40.

Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.

Röllig C, Bornhäuser M, Kramer M, Thiede C, Ho AD, Krämer A, Schäfer-Eckart K, Wandt H, Hänel M, Einsele H, Aulitzky WE, Schmitz N, Berdel WE, Stelljes M, Müller-Tidow C, Krug U, Platzbecker U, Wermke M, Baldus CD, Krause SW, Stölzel F, von Bonin M, Schaich M, Serve H, Schetelig J, Ehninger G.

J Clin Oncol. 2015 Feb 10;33(5):403-10. doi: 10.1200/JCO.2013.54.4973. Epub 2014 Dec 29. Erratum in: J Clin Oncol. 2015 May 1;33(13):1519.

PMID:
25547501
41.

Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial.

Schetelig J, Schaich M, Schäfer-Eckart K, Hänel M, Aulitzky WE, Einsele H, Schmitz N, Rösler W, Stelljes M, Baldus CD, Ho AD, Neubauer A, Serve H, Mayer J, Berdel WE, Mohr B, Oelschlägel U, Parmentier S, Röllig C, Kramer M, Platzbecker U, Illmer T, Thiede C, Bornhäuser M, Ehninger G; Study Alliance Leukemia.

Leukemia. 2015 May;29(5):1060-8. doi: 10.1038/leu.2014.335. Epub 2014 Dec 1.

PMID:
25434303
42.

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial.

Hoelzer D, Walewski J, Döhner H, Viardot A, Hiddemann W, Spiekermann K, Serve H, Dührsen U, Hüttmann A, Thiel E, Dengler J, Kneba M, Schaich M, Schmidt-Wolf IG, Beck J, Hertenstein B, Reichle A, Domanska-Czyz K, Fietkau R, Horst HA, Rieder H, Schwartz S, Burmeister T, Gökbuget N; German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia.

Blood. 2014 Dec 18;124(26):3870-9. doi: 10.1182/blood-2014-03-563627. Epub 2014 Oct 30.

43.

CD133-targeted gene transfer into long-term repopulating hematopoietic stem cells.

Brendel C, Goebel B, Daniela A, Brugman M, Kneissl S, Schwäble J, Kaufmann KB, Müller-Kuller U, Kunkel H, Chen-Wichmann L, Abel T, Serve H, Bystrykh L, Buchholz CJ, Grez M.

Mol Ther. 2015 Jan;23(1):63-70. doi: 10.1038/mt.2014.173. Epub 2014 Sep 5. Erratum in: Mol Ther. 2015 Apr;23(4):790.

44.

PADI4 acts as a coactivator of Tal1 by counteracting repressive histone arginine methylation.

Kolodziej S, Kuvardina ON, Oellerich T, Herglotz J, Backert I, Kohrs N, Buscató El, Wittmann SK, Salinas-Riester G, Bonig H, Karas M, Serve H, Proschak E, Lausen J.

Nat Commun. 2014 May 29;5:3995. doi: 10.1038/ncomms4995.

45.

A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis.

Berg T, Thoene S, Yap D, Wee T, Schoeler N, Rosten P, Lim E, Bilenky M, Mungall AJ, Oellerich T, Lee S, Lai CK, Umlandt P, Salmi A, Chang H, Yue L, Lai D, Cheng SW, Morin RD, Hirst M, Serve H, Marra MA, Morin GB, Gascoyne RD, Aparicio SA, Humphries RK.

Blood. 2014 Jun 19;123(25):3914-24. doi: 10.1182/blood-2012-12-473439. Epub 2014 May 6.

46.

[Patient blood management--How does it work in practice?--the interdisciplinary cooperation].

Müller MM, Meybohm P, Geisen C, Schmitz-Rixen T, Serve H, Seifried E, Zacharowski K.

Anasthesiol Intensivmed Notfallmed Schmerzther. 2014 Apr;49(4):266-72. doi: 10.1055/s-0034-1373806. Epub 2014 May 2. Review. German.

PMID:
24792600
47.

Global phosphoproteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinib.

Schaab C, Oppermann FS, Klammer M, Pfeifer H, Tebbe A, Oellerich T, Krauter J, Levis M, Perl AE, Daub H, Steffen B, Godl K, Serve H.

Leukemia. 2014 Mar;28(3):716-9. doi: 10.1038/leu.2013.347. Epub 2013 Nov 19. No abstract available.

48.

Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis.

Chromik J, Safferthal C, Serve H, Fulda S.

Cancer Lett. 2014 Mar 1;344(1):101-109. doi: 10.1016/j.canlet.2013.10.018. Epub 2013 Oct 30.

PMID:
24184825
49.

Cutting edge: feed-forward activation of phospholipase Cγ2 via C2 domain-mediated binding to SLP65.

Engelke M, Oellerich T, Dittmann K, Hsiao HH, Urlaub H, Serve H, Griesinger C, Wienands J.

J Immunol. 2013 Dec 1;191(11):5354-8. doi: 10.4049/jimmunol.1301326. Epub 2013 Oct 28.

50.

Chemomodulation of sequential high-dose cytarabine by fludarabine in relapsed or refractory acute myeloid leukemia: a randomized trial of the AMLCG.

Fiegl M, Unterhalt M, Kern W, Braess J, Spiekermann K, Staib P, Grüneisen A, Wörmann B, Schöndube D, Serve H, Reichle A, Hentrich M, Schiel X, Sauerland C, Heinecke A, Rieger C, Beelen D, Berdel WE, Büchner T, Hiddemann W; German AML Cooperative Group (AMLCG).

Leukemia. 2014 May;28(5):1001-7. doi: 10.1038/leu.2013.297. Epub 2013 Oct 22.

PMID:
24150216

Supplemental Content

Support Center